Investors may be wondering whether Haemonetics at around US$74 is offering value right now, or whether the market is still undecided about its future potential. The stock has been quite mixed lately, ...

Haemonetics will shell out up to 185 million euros ($216 million) to acquire Vivasure Medical, a Galway, Ireland-based medtech that makes arterial closure devices.

Analysts have recently evaluated Haemonetics and provided 12-month price targets. The average target is $87.45, accompanied ...

Haemonetics (NYSE: HAE) announced today that it acquired percutaneous vessel closure device maker Vivasure Medical.

Haemonetics has acquired Vivasure, an Ireland-based company developing next-generation technology for percutaneous vessel ...

Haemonetics (HAE) to acquire Vivasure Medical Limited for 100 million euros upfront plus potential milestone payments.

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ...

Why Haemonetics’ Price Target Just Nudged Higher Haemonetics’ fair value estimate has been nudged higher from about US$90.20 ...

Orchestra BioMed (Nasdaq:OBIO) expects to receive up to $21 million in cash as a result of Haemonetics' recent.

$11 million in proceeds expected to be received during 2026, with remainder of expected proceeds to be received in future revenue earnouts Vivasure Medical Limited (“Vivasure”) has been a strategic ...

Haemonetics' acquisition of Vivasure adds PerQseal Elite, advancing large-bore closure solutions for TAVR and EVAR markets.